Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
This article was published in the SA Journal of Oncology, 01 October 2020 https://doi.org/10.4102/sajo.v4i0.138
Introduction:
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare neoplasms arising from
the endocrine cells of the gastrointestinal (GI) tract and the pancreas that secrete serotonin and
other peptides.1 This secretion causes a complex clinical spectrum, including carcinoid syndrome
(e.g. diarrhoea and skin flushing), which affects the patients’ health-related quality of life (HR-QoL).